"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
DeJong C, Masuda C, Chen R, Kazi DS, Dudley RA, Tseng CW. Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D. JAMA Intern Med. 2020 12 01; 180(12):1696-1699.
-
Davidson MB. Metformin Should Not Be Used to Treat Prediabetes. Diabetes Care. 2020 09; 43(9):1983-1987.
-
Wang CY, Pham PN, Kim S, Lingineni K, Schmidt S, Diaby V, Brown J. Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States. Clin Transl Sci. 2020 03; 13(2):352-361.
-
Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 10; 20(5):724-735.
-
Okere AN, Ezendu K, Berthe A, Diaby V. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2018 Feb; 24(2):142-152.
-
Nguyen E, Coleman CI, Nair S, Weeda ER. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications. 2018 02; 32(2):210-215.
-
Lum CJ, Nakagawa K, Shohet RV, Seto TB, Taira DA. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. Hawaii J Med Public Health. 2017 04; 76(4):99-102.
-
Diaby V, Adunlin G, Montero AJ. Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88. J Med Econ. 2014 Apr; 17(4):248-9.
-
Amoroso A, Etienne-Mesubi M, Edozien A, Ojoo S, Sheneberger R, Obiefune M, Hossain MB, Stafford K, Redfield RR. Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):314-20.
-
Diaby V, Lachaine J. An application of a proposed framework for formulary listing in low-income countries: the case of C?te d'Ivoire. Appl Health Econ Health Policy. 2011 Nov 01; 9(6):389-402.